$INSILICO(03696.HK) has surged by over a dozen points, and the catalysts are quite clear: ISM8969, an NLRP3 inhibitor discovered by AI, has completed its first human dosing in collaboration with Hengtai Biotech, marking the first true clinical milestone in its AI drug development pipeline. At the same time, it was included in the FTSE Global Index, and passive funds typically front-run before the effective date. One fundamental milestone and one capital flow factor combined, this rally has a solid basis and is not purely speculative.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
